Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22662461 | 0.91 | DGKA (0.43) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL813361 | 0.89 | ADRA2A (0.54) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL141329 | 0.87 | DGKA (0.50) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL28222618 | 0.87 | ALDH1A1 (0.52) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL1760113 | 0.87 | MGLL (0.43) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL107227 | 0.84 | — | — | |
| SCHEMBL813905 | 0.84 | DGKA (0.58) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL1033327 | 0.84 | DGKA (0.64) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL813660 | 0.84 | DGKA (0.58) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL11355793 | 0.84 | ADRA2A (0.40) | DGKAADRA2AADRA1AMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251430-A1 | METHOD FOR PRODUCING BETA-ALKOXYPROPIONAMIDE | IDEMITSU KOSAN CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251430-A1 | METHOD FOR PRODUCING BETA-ALKOXYPROPIONAMIDE | IDEMITSU KOSAN CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2374789-A1 | METHOD FOR PRODUCING BETA-ALKOXYPROPIONAMIDE | Idemitsu Kosan Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251430-A1 | METHOD FOR PRODUCING BETA-ALKOXYPROPIONAMIDE | NAAA, APEH, ACSL3 | DGKA 550/4885ADRA2A 290/4885ADRA1A 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.